The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 109:881-888, June 1953
doi: 10.1176/appi.ajp.109.12.881
© 1953 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by MAY, P. R. A.
* Articles by EBAUGH, F. G.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by MAY, P. R. A.
* Articles by EBAUGH, F. G.

DORMISON, A NEW TYPE OF HYPNOTIC

Its Therapeutic Use in Psychiatric Patients

PHILIP R. A. MAY M. D.1, and FRANKLIN G. EBAUGH M. D.1

1 The Department of Psychiatry, University of Colorado School of Medicine.

Dormison is a drug of a new type that, when used as a hypnotic, is highly efficient and relatively nontoxic and noncumulative. It is the hypnotic of choice in elderly, senile, and arteriosclerotic patients and it has definite advantages over other hypnotics in other types of patients.

The hypnotic effect is highly specific, and Dormison is of little value as a sedative since toxic or near-toxic doses are required to produce an adequate sedative effect in disturbed patients. We have observed cumulative effects only when large doses were given as a sedative.

The danger of addiction may be less than with other hypnotic-sedative drugs, as Dormison is ultra-short-acting and tends to lack their stupefying and euphorigenic action. Nevertheless, Dormison should not be given as a sedative to patients who have previously been addicted to other drugs, and it should be used as a hypnotic in these cases only under hospital conditions. In view of previous reports, and our findings on cumulation and addiction, barbiturates should not be given to patients receiving Dormison until such time as extensive data are available on the potentiating effect of Dormison on barbiturates in man.







Get information about faster international access.

Privacy Policy

Copyright © 1953 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org